切换至 "中华医学电子期刊资源库"

中华妇幼临床医学杂志(电子版) ›› 2015, Vol. 11 ›› Issue (01) : 90 -94. doi: 10.3877/cma.j.issn.1673-5250.2015.01.021

所属专题: 文献

综述

卵巢恶性肿瘤的影像学诊断进展
陈荟竹1, 王梦甜1   
  1. 1. 610041 成都,四川大学华西第二医院放射科
  • 收稿日期:2014-10-10 修回日期:2015-01-02 出版日期:2015-02-01

Diagnosis progress of malignant tumor of ovary in imageology

Huizhu Chen1, Mengtian Wang1   

  1. 1. Department of Radiology, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
  • Received:2014-10-10 Revised:2015-01-02 Published:2015-02-01
  • About author:
    Corresponding author: Ning Gang, Email:
引用本文:

陈荟竹, 王梦甜. 卵巢恶性肿瘤的影像学诊断进展[J/OL]. 中华妇幼临床医学杂志(电子版), 2015, 11(01): 90-94.

Huizhu Chen, Mengtian Wang. Diagnosis progress of malignant tumor of ovary in imageology[J/OL]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2015, 11(01): 90-94.

卵巢癌是妇科恶性肿瘤中严重威胁女性健康的一种疾病,起病隐匿、发展快,导致的患者死亡率高,早期诊断和早期治疗可显著提高患者生存率。笔者主要关注超声、CT、MRI及正电子发射计算机断层显像(PET)/CT等影像学检查方法在卵巢癌诊断、临床分期及术后随访中应用价值的研究进展,进行综述如下。

Ovarian cancer is the leading cause of death among gynecological malignancies, with its asymptomatic and rapid disease progression. Early diagnosis and correct treatment can significantly improve ovarian cancer patients' survival. In this article, we will describe the application of ultrasonography, CT, MRI and positron emission tomography (PET)/CT in the diagnosis, staging and follow-up of ovarian cancer.

表1 2014年卵巢癌、输卵管癌及原发性腹膜癌TNM分类和FIGO分期系统
Table 1 2014 TNM and FIGO staging classification system for ovarian, fallopian tube and peritoneal cancer
TNM分类 FIGO临床分期 临床表现
T1-N0-M0 肿瘤局限于卵巢或输卵管
T1a-N0-M0 A 肿瘤局限于单侧卵巢(包膜完整)或输卵管,其表面无肿瘤,腹水或腹腔冲洗液中无恶性肿瘤细胞
T1b-N0-M0 B 肿瘤局限于双侧卵巢(包膜完整)或输卵管,其表面无肿瘤,腹水或腹腔冲洗液中无恶性肿瘤细胞
T1c-N0-M0 C 肿瘤局限于单侧或双侧卵巢或输卵管,并且有以下(ⅠC1~ⅠC3)情况之一:
T1c1-N0-M0 C1 手术导致肿瘤包膜破裂
T1c2-N0-M0 C2 手术前肿瘤包膜已破裂或卵巢、输卵管表面有肿瘤
T1c3-N0-M0 C3 腹水或腹腔冲洗液发现癌细胞
T2-N0-M0 肿瘤累及单侧或双侧卵巢或输卵管并伴盆腔播散(骨盆入口平面以下)或原发性腹膜癌
T2a-N0-M0 A 肿瘤蔓延至或种植到子宫和(或)输卵管和(或)卵巢
T2b-N0-M0 B 肿瘤蔓延至其他盆腔内组织
T1/T2-N1-M0 肿瘤累及单侧或双侧卵巢、输卵管或原发性腹膜癌,伴有细胞学或组织学证实的盆腔外腹膜转移或证实存在腹膜后淋巴结转移
T3a1-N1-M0 A1 仅有腹膜后淋巴结阳性(细胞学或组织学证实)
? A1(i) 转移灶最大直径≤10 mm
? A1(ii) 转移灶最大直径>10 mm
T3a2-N0/N1-M0 A2 显微镜下盆腔外腹膜受累,伴或不伴腹膜后阳性淋巴结
T3b-N0/N1-M0 B 盆腔外腹膜腔内肉眼可见转移,但转移灶最大径≤2 cm,伴或不伴腹膜后阳性淋巴结
T3c-N0/N1-M0 C 盆腔外腹膜腔内肉眼可见转移,转移灶最大径>2 cm,伴或不伴腹膜后阳性淋巴结(包括肿瘤蔓延至肝包膜和脾,但无转移到实质脏器证据)
? 腹膜转移外的远处转移
任何T,任何N A 胸腔积液中发现癌细胞
M1 B 腹腔外实质器官转移(包括肝实质转移和腹股沟淋巴结、腹腔外阳性淋巴结)
[1]
Jemal A, Siegel R, Ward E. Cancer statistics, 2010[J]. CA Cancer J Clin,2010,60(5):277–300.
[2]
Mohagheqh P, Rockall AG. Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques[J].Radiographics, 2012, 32(6):1751–1773.
[3]
Lutz AM, Willmann JK, Drescher CW,et al. Early diagnosis of ovarian carcinoma:is a solution in sight? [J].Radiology, 2011,259(2):329–345.
[4]
Bharwani N, Reznek RH, Rockall AG. Ovarian cancer management: the role of imaging and diagnostic challenges[J]. Eur J Radiol,2011,78(1):41–51.
[5]
Huchon C, Metzqer U, Bats AS,et al. Value of three-dimensional contrast-enhanced power Doppler ultrasound for characterizing adnexal masses[J]. J Obstet Gynaecol Res,2012,38(5):832–840.
[6]
Gatreh-Samani F, Tarzamni MK, Olad-Sahebmadarek E, et al. Accuracy of 64-multidetector computed tomography in diagnosis of adnexal tumors[J]. J Ovarian Res, 2011, 4(1):15.
[7]
Medeiros LR, Freitas LB,Rosa DD, et al. Accuracy of magnetic resonance in ovarian tumor:a systematic quantitative review[J]. Am J Obstet Gynecol, 2011,204(1):67,e1-e10.
[8]
Thomassin-Naggara I, Balvay D, Aubert E, et al. Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study[J]. Eur Radiol,2012,22(4):738–745.
[9]
Li W, Chu C, Cui Y, et al. Diffusion-weighted MRI: a useful technique to discriminate benign versus malignant ovarian surface epithelial tumors with solid and cystic components[J]. Abdom Imaging,2012,37(5):897–903.
[10]
Kitajima K, Suzuki K, Senda M, et al. FDG-PET/CT for diagnosis of primary ovarian cancer[J]. NucI Med Commun, 2011,32(7):549–553.
[11]
Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer:correlation between PET/CT,Doppler US, and CT or MRI[J]. Gynecol Oncol, 2010,116(3):389–394.
[12]
Kitajima K, Murakami K, Sakamoto S, et al. Present and future of FDG-PET/CT in ovarian cancer[J]. Ann Nucl Med,2011,25(3):155–164.
[13]
Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer[J]. Gynecol Oncol, 2014, 133(3):401–404.
[14]
Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum[J]. Int J Gynaecol Obstet, 2014,124(1):1–5.
[15]
杨华,郎景和. 欧洲肿瘤内科协会对非上皮性卵巢癌的诊断、治疗和随访所制定的临床实践指南[J]. 国际妇产科学杂志,2011,38(4):339–342.
[16]
Moyle P, Addlev HC, Sala E. Radiological staging of ovarian carcinoma[J]. Semin Ultrasound CT MR,2010,31(5):388–398.
[17]
Forstner R, Sala E, Kinkel K, et al. ESUR guidelines: ovarian cancer staging and follow-up[J]. Eur Radiol,2010,20(12):2773–2780.
[18]
Moyle P, Addley HC, Sala E. Radiological staging of ovarian carcinoma[J].Semin Ultrasound CT MR, 2010,31(5):388–398.
[19]
Bharwani N, Reznek RH, Rockall AG.. Ovarian cancer management: the role of imaging and diagnostic challenges[J]. Eur J Radiol, 2011,78(1):41–51.
[20]
Metser U, Jones C, Jacks LM, et al. Identification and quantification of peritoneal metastases in patients with ovarian cancer with multidetector computed tomography correlation with surgery and surgical outcome[J]. Int Gynecol Cancer,2011,21(8):1391–1398.
[21]
Sala E, Rockall AG, Freeman SJ, et al. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies:what the radiologist needs to know[J]. Radiology,2013,266(3):717–740.
[22]
Lew A, Medjhoul A, Caramella C, et al. Interest of diffusion-weighted echo-planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: a review[J]. J Magn Reson Imaging,2011,33(5):1020–1027.
[23]
王春美,张孟超,刘云霞. 磁共振弥散加权成像在卵巢癌腹膜转移中的应用[J]. 实用妇产科杂志,2012,28(3):180–182.
[24]
Lee HJ, Luci JJ, Tantawy MN, et al. Detecting peritoneal dissemination of ovarian cancer in mice by DWIBS[J]. Magn Reson Imaging,2013,31(2):227–234.
[25]
宋金国,张红霞. 弥散加权背景抑制成像在卵巢癌分期的应用探讨[J]. 中国现代医生,2010,48(1):60–61.
[26]
Fuccio C, Castellucci P, Marzola MC, et al. Noninvasive and invasive staging of ovarian cancer review of the literature[J].Clin Nuce Med,2011,36(10):889–893.
[27]
Yuan Y, Gu ZX, Tao XF, et al. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a Meta-analysis[J]. Eur J Radiol,2012,81(5):1002–1006.
[28]
Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer[J]. Crit Rev Oncol Hematol,2009,71(1):43–52.
[29]
Gu P, Pan LL, Wu SQ, et al. CA125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma:a systematic review and Meta-analysis[J]. Eur J Radiol, 2009,71(2):164–174.
[30]
Antunovic L, Cimitan M, Borsatti E, et al. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas[J]. Clin Nucl Med,2012, 37(2):e184–e188.
[31]
葛海云,蒋创. 18F-FDG PET/CT在卵巢癌术后复发、转移监测中的应用[J]. 南京医科大学学报,2010,30(8):1203–1205.
[32]
Wang L, Neoh KG, Kang ET, et al. Multifunctional polyglycerol-grafted Fe3O4 & SiO2 nanoparticles for targeting ovarian cancer cells[J]. Biomaterials,2011,32(8):2166–2173.
[33]
Sukerkar PA, MacRenaris KW, Townsend TR, et al. Synthesis and biological evaluation of water-soluble progesterone-conjugated probes for magnetic resonance imaging of hormone related cancers[J]. Bioconiug Chem,2011,22(11):2304–2316.
[1] 章建全, 程杰, 陈红琼, 闫磊. 采用ACR-TIRADS评估甲状腺消融区的调查研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 966-971.
[2] 罗辉, 方晔. 品管圈在提高甲状腺结节细针穿刺检出率中的应用[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 972-977.
[3] 杨忠, 时敬业, 邓学东, 姜纬, 殷林亮, 潘琦, 梁泓, 马建芳, 王珍奇, 张俊, 董姗姗. 产前超声在胎儿22q11.2 微缺失综合征中的应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 852-858.
[4] 孙佳丽, 金琳, 沈崔琴, 陈晴晴, 林艳萍, 李朝军, 徐栋. 机器人辅助超声引导下经皮穿刺的体外实验研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 884-889.
[5] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[6] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[7] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[8] 项文静, 徐燕, 茹彤, 郑明明, 顾燕, 戴晨燕, 朱湘玉, 严陈晨. 神经学超声检查在产前诊断胼胝体异常中的应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 470-476.
[9] 胡可, 鲁蓉. 基于多参数超声特征的中老年女性压力性尿失禁诊断模型研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 477-483.
[10] 卢菊, 赵胜, 范建华, 高艳多. 探讨IOTA、GI-RADS及O-RADS在附件肿瘤良恶性鉴别诊断中的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 484-490.
[11] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[12] 刘明辉, 葛方明. MRI 对腹股沟疝修补术后患者早期并发症的评估价值研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 579-583.
[13] 张琛, 秦鸣, 董娟, 陈玉龙. 超声检查对儿童肠扭转缺血性改变的诊断价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 565-568.
[14] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[15] 张立俊, 孙存杰, 胡春峰, 孟冲, 张辉. MSCT、DCE-MRI 评估术前胃癌TNM 分期的准确性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 519-523.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?